Area of research
Public Health, Environmental and Occupational Health · General Health Professions
Research interest
Research interests include Medicine, Nivolumab, Tolerability, Adverse effect, Internal medicine, and Pembrolizumab.
INTerpath-001: Pembrolizumab with V940 (mRNA-4157) versus pembrolizumab with placebo for adjuvant treatment of high-risk stage II-IV melanoma.
Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors
EUR Research Repository (Erasmus University Rotterdam) 2022cited by 50position: middle
Design and Implementation of a Curriculum for Emergency Medicine Residents to Address Medications and Treatment Referral for Opioid Use Disorder
Abstract B057: BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors